US 11,654,179 B2
Compositions, methods and kits for treating complement related disorders
Rajendra Kumar-Singh, Weston, MA (US); Derek Leaderer, Boston, MA (US); and Siobhan M. Cashman, Boston, MA (US)
Assigned to Trustees of Tufts College, Medford, MA (US)
Filed by Trustees of Tufts College, Medford, MA (US)
Filed on Oct. 9, 2020, as Appl. No. 17/67,515.
Application 17/067,515 is a continuation of application No. 15/444,500, filed on Feb. 28, 2017, granted, now 10,813,977.
Application 15/444,500 is a continuation of application No. PCT/US2015/047405, filed on Aug. 28, 2015.
Claims priority of provisional application 62/043,084, filed on Aug. 28, 2014.
Prior Publication US 2021/0138031 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 38/17 (2006.01); C07K 14/705 (2006.01); A61P 37/00 (2006.01); A47K 7/02 (2006.01); B08B 7/02 (2006.01); B25G 1/04 (2006.01); B25G 1/06 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01)
CPC A61K 38/177 (2013.01) [A47K 7/026 (2013.01); A61K 45/06 (2013.01); A61P 37/00 (2018.01); B08B 7/02 (2013.01); B25G 1/04 (2013.01); B25G 1/06 (2013.01); C07K 14/70596 (2013.01); G01N 33/6893 (2013.01); G01N 2333/4716 (2013.01)] 27 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising a recombinant chimeric protein having amino acid sequences from at least two complement inhibitor proteins: a CD46, a CD55, and a CD59; or a nucleotide sequence encoding the recombinant chimeric protein, wherein the sequences and order of the sequences comprising the recombinant chimeric protein in the pharmaceutical composition is selected from the group consisting of: CD55 and CD59 as shown in SEQ ID NO: 2; and CD46, CD55 and CD59 as shown in SEQ ID NO: 4.